Source: Reuters U.S. healthcare giant Johnson & Johnson (JNJ.N) will buy Swiss biotech company Actelion (ATLN.S) in a $30 billion all-cash deal that includes spinning off Actelion's research and development pipeline, the companies said on Thursday. The biggest European drugs takeover in 13 years gives J&J access to the Swiss…...